Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis

被引:29
作者
Piketty, C
Bardin, C
Gilquin, J
Gairard, A
Kazatchkine, MD
Chast, F
机构
[1] Hop Broussais, INSERM U430, Dept Clin Immunol, F-75674 Paris, France
[2] Hotel Dieu, Dept Pharm Pharmacol Toxicol, Paris, France
关键词
cytomegalovirus; oral ganciclovir; ganciclovir plasma levels;
D O I
10.1046/j.1469-0691.2000.00014.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir therapy are associated with recurrence of CMV retinitis. Methods A prospective study of the plasma concentration of ganciclovir after initiation of maintenance oral ganciclovir therapy in 14 AIDS patients who had recovered from acute cytomegalovirus (CMV) retinitis. Results Five of the 14 patients exhibited a mean time to recurrence of 37 days. The mean trough plasma concentration of ganciclovir in these patients after 1 month of oral ganciclovir therapy, was 0.40 +/- 0.30 mg/L. Nine patients had a mean time of progression of 263 days. The mean trough plasma concentration of ganciclovir in the latter patients was 0.80 +/- 0.60 mg/L. Conclusions Patients exhibiting trough plasma levels of ganciclovir below 0.6 mg/L may be at higher risk of progression than patients who exhibited levels above 0.6 mg/L.
引用
收藏
页码:117 / 120
页数:4
相关论文
共 20 条
  • [1] GANCICLOVIR ABSOLUTE BIOAVAILABILITY AND STEADY-STATE PHARMACOKINETICS AFTER ORAL-ADMINISTRATION OF 2 3000-MG/D DOSING REGIMENS IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE AND CYTOMEGALOVIRUS-SEROPOSITIVE PATIENTS
    ANDERSON, RD
    GRIFFY, KG
    JUNG, D
    DORR, A
    HULSE, JD
    SMITH, RB
    [J]. CLINICAL THERAPEUTICS, 1995, 17 (03) : 425 - 432
  • [2] BARDIN C, 1993, P 22 EUR S CLIN PHAR, P114
  • [3] INVITRO SUSCEPTIBILITY OF CYTOMEGALOVIRUS ISOLATES FROM IMMUNOCOMPROMISED PATIENTS TO ACYCLOVIR AND GANCICLOVIR
    COLE, NL
    BALFOUR, HH
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1987, 6 (03) : 255 - 261
  • [4] COOPER D, 1995, AIDS, V9, P471, DOI 10.1097/00002030-199509050-00009
  • [5] Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir
    Drew, WL
    Stempien, MJ
    Andrews, J
    Shadman, A
    Tan, SJ
    Miner, R
    Buhles, W
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) : 1352 - 1355
  • [6] ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
    DREW, WL
    IVES, D
    LALEZARI, JP
    CRUMPACKER, C
    FOLLANSBEE, SE
    SPECTOR, SA
    BENSON, CA
    FRIEDBERG, DN
    HUBBARD, L
    STEMPIEN, MJ
    SHADMAN, A
    BUHLES, W
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) : 615 - 620
  • [7] PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS
    ERICE, A
    CHOU, S
    BIRON, KK
    STANAT, SC
    BALFOUR, HH
    JORDAN, MC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) : 289 - 293
  • [8] Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics
    Filler, G
    Lampe, D
    von Bredow, MA
    Lappenberg-Pelzer, M
    Rocher, S
    Strehlau, J
    Ehrich, JHH
    [J]. PEDIATRIC NEPHROLOGY, 1998, 12 (01) : 6 - 9
  • [9] INCIDENCE AND NATURAL-HISTORY OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE
    GALLANT, JE
    MOORE, RD
    RICHMAN, DD
    KERULY, J
    CHAISSON, RE
    BARTLETT, J
    MCAVINUE, S
    BRYSON, Y
    COHEN, H
    FISCHL, M
    BOLIN, T
    KESSLER, H
    BURROUGH, Y
    MILDVAN, D
    FOX, A
    RICHMAN, D
    FREEMAN, B
    SIMON, G
    GRABOWY, KW
    CHERNOFF, D
    DUFF, P
    THOMPSON, S
    BARRETT, K
    AWE, R
    CHAPMAN, R
    LEONARD, S
    BAINES, L
    TURNER, P
    HAWKINS, M
    MURRAY, H
    BOWERS, J
    LANE, C
    TILSON, H
    ANDREWS, E
    SMILEY, L
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) : 1223 - 1227
  • [10] Griffy KG, 1996, AIDS, V10, pS3